黄永焯,研究员
中国科学院上海药物研究所/中山药物创新研究院研究员,研究方向包括药物新剂型与递药新技术。共发表SCI论文150余篇。科技部中青年创新领军人才、上海浦江人才计划。获得国家优秀青年基金和杰出青年基金、中国药学会-赛诺菲青年生物药物奖。现任International Journal of Pharmaceutics亚洲区编辑,Nano Letters, Journal of Controlled Release, Acta Pharmaceutica Sinica B, Cancer Biology & Medicine, Medicine in Drug Discovery编委,并担任多个国内中文期刊编委。担任中国药学会药剂学专委会委员、中国药学会纳米药学专委会委员、中国抗癌协会纳米肿瘤学专委会常务委员等。
代表论著:
1.Tu B#, Wang Y#,* An X, Qu J, Li Q, Gao Y, Shi M, Qiu H, Huang YZ*, Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. Acta Pharmaceutica Sinica B 2022: 3187-3194.
2.Wu CH#, Xu Q#, Wang HY*, Zeng JX, Tu B, Zhao PF, Shi MJ, Qiu H*, Huang YZ*. Neutralization of SARS-CoV-2 Pseudovirus Using ACE2-Engineered Extracellular Vesicles. Acta Pharmaceutica Sinica B 2022: 1523 (封底论文)
3.Zhao P, Qu J, Wu A, Wang S, Tang X, Ou A, Zhang J, Xu Y, Zhao Q*, Huang YZ*, Anti-alcoholism drug disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination. Nano Today 2022: 101448
4.Zhen ZN, Zhang JX, Jiang JZ, He Y, Zhang WY, Mo XP, Kang XJ, Xu Q*, Wang B, Huang YZ*. Remodeling Tumor Immune Microenvironment (TIME) for Glioma Therapy Using Multi-Targeting Liposomal Codelivery. Journal for ImmunoTherapy of Cancer, 2020: e000207.
5.Zhao PF, Wang YH, Kang XJ, Wu AH, Yin WM, Tang YS, Wang JY, Zhang M, Duan Y and Huang YZ*. Dual-Targeting Biomimetic Delivery for Antiglioma via Remodeling Tumor Microenvironment and Directing Macrophage-Mediated Immunotherapy. Chemical Science 2018: 2674–2689